Skip to main content

Artiva Biotherapeutics, Inc.

corporate_fare Company Profile

Artiva Biotherapeutics, Inc.

ARTV·NASDAQ·Life Sciences·CIK 0001817241

Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company developing natural killer (NK) cell-based therapies for autoimmune diseases and cancers. The company's product candidates are derived from donor cells (allogeneic), pre-manufactured, and stored frozen for immediate shipment, making them "off-the-shelf." Artiva's lead product candidate is AlloNK (also known as AB-101), an allogeneic, non-genetically modified, cryopreserved NK cell therapy. AlloNK is designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of monoclonal antibodies (mAbs) to drive B-cell depletion. The company is evaluating AlloNK in three ongoing clinical trials for B-cell driven autoimmune diseases, including a company-sponsored basket trial that includes rheumatoid arthritis (RA) and Sjögren's disease (SjD). Refractory RA is the lead indication for AlloNK development. In November 2025, Artiva reported data from 32 patients with autoimmune disease treated with AlloNK plus anti-CD20 monoclonal antibody (mAb) as of October 1, 2025. This data showed consistent and complete B-cell depletion by Day 13 of treatment in all patients treated with AlloNK + mAb with samples analyzed.

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 28 items for ARTV at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-09, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 10/10, with 15 rated 8 or above. Recent SEC coverage for ARTV spans 10-Q, 8-K, SCHEDULE 13D/A, 4.

Recent high-impact activity:

  • Artiva 10-Q: $319M Cash After AlloNK Wind-Down, $27-35M Restructuring Costs
  • Artiva Halts AlloNK After Two Patient Deaths, Cuts 94% of Staff, Pursues Strategic Alternatives
  • Artiva Scraps Lead AlloNK Program After Grade 5 Safety Events, Cuts 94% of Staff
  • AlloNK Shows Strong Sjögren Efficacy and Clean Safety in Phase 2a
  • Artiva Biotherapeutics Q2 2026: RMAT Designation, Phase 3 on Track, Cash Runway into 2029

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$0
Net Income
-$83.86M
Diluted EPS
-$3.43
Op. Cash Flow
-$76.75M
Free Cash Flow
-$79.34M
Operating Income
-$89.81M
Cash & Equivalents
$26.7M
Debt / Equity
0.00×
Shares Outstanding
24.44M sh
Source: 10-K · filed 2026-04-30 · accession 0001193125-26-197115

Short Interest & Short Volume

1.81 days to cover

FINRA reported short interest of 2,953,973 shares in ARTV as of the October 30, 2026 settlement, a 7.9% increase from the prior period — about 1.8 days to cover at its recent average daily volume. On November 20, 2026, 69.6% of ARTV volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)2,953,973 shares as of October 30, 2026
Change vs prior period▲ 7.9%
Days to cover1.81 at avg daily volume of 1,636,203
Daily short volume (FINRA facilities)69.6% of 890,511 shares on November 20, 2026
5-day average short volume67.3%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Moderate risk

Filing-implied dilution signals for ARTV, detected from its recent SEC filings.

ATM program1 shelf registration

$400M Shelf Registration Filed · $100M ATM Program Included

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with A →
$3.82 +1.06% today
52-week range · as of 2026-11-09 $2.96 – $14.53
Market cap
$186.85M
Volume
1.8M (1.5× avg)
3-mo avg 1.2M
Live data · 2026-11-22 12:31 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ARTV - Latest Insights

ARTV
Nov 09, 2026, 4:04 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $4.22
Real-time Price: $3.82 info
Change: -$0.400 (-9%) info
Market Cap: $186.854M info
ARTV
Oct 27, 2026, 8:30 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $4.09
Real-time Price: $3.82 info
Change: -$0.270 (-7%) info
Market Cap: $186.854M info
ARTV
Oct 27, 2026, 7:30 AM EDT
Source: Wiseek News
Importance Score:
10
Price at Filing: $6.30
Real-time Price: $3.82 info
Change: -$2.48 (-39%) info
Market Cap: $186.854M info
ARTV
Oct 01, 2026, 7:30 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $7.25
Real-time Price: $3.82 info
Change: -$3.43 (-47%) info
Market Cap: $186.854M info
ARTV
Aug 06, 2026, 4:09 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $11.58
Real-time Price: $3.82 info
Change: -$7.76 (-67%) info
Market Cap: $186.854M info
ARTV
Jul 23, 2026, 9:23 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
9
Price at Filing: $10.13
Real-time Price: $3.82 info
Change: -$6.31 (-62%) info
Market Cap: $186.854M info
ARTV
Jul 23, 2026, 9:22 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $10.13
Real-time Price: $3.82 info
Change: -$6.31 (-62%) info
Market Cap: $186.854M info
ARTV
Jul 20, 2026, 6:08 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $9.12
Real-time Price: $3.82 info
Change: -$5.30 (-58%) info
Market Cap: $186.854M info
ARTV
Jun 16, 2026, 6:08 PM EDT
Filing Type: 4
Importance Score:
9
Price at Filing: $8.90
Real-time Price: $3.82 info
Change: -$5.08 (-57%) info
Market Cap: $186.854M info
ARTV
Jun 15, 2026, 7:37 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $9.37
Real-time Price: $3.82 info
Change: -$5.55 (-59%) info
Market Cap: $186.854M info
ARTV
Jun 11, 2026, 7:36 PM EDT
Filing Type: 4
Importance Score:
9
Price at Filing: $7.60
Real-time Price: $3.82 info
Change: -$3.78 (-50%) info
Market Cap: $186.854M info
ARTV
May 28, 2026, 4:38 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
9
Price at Filing: $8.25
Real-time Price: $3.82 info
Change: -$4.43 (-54%) info
Market Cap: $186.854M info
ARTV
May 28, 2026, 4:34 PM EDT
Filing Type: 4
Importance Score:
9
Price at Filing: $7.61
Real-time Price: $3.82 info
Change: -$3.79 (-50%) info
Market Cap: $186.854M info
ARTV
May 19, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $8.55
Real-time Price: $3.82 info
Change: -$4.73 (-55%) info
Market Cap: $186.854M info
ARTV
May 19, 2026, 8:07 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $9.20
Real-time Price: $3.82 info
Change: -$5.38 (-58%) info
Market Cap: $186.854M info
ARTV
May 13, 2026, 5:47 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
9
Price at Filing: $10.58
Real-time Price: $3.82 info
Change: -$6.76 (-64%) info
Market Cap: $186.854M info
ARTV
May 13, 2026, 5:45 PM EDT
Filing Type: 4
Importance Score:
9
Price at Filing: $10.29
Real-time Price: $3.82 info
Change: -$6.47 (-63%) info
Market Cap: $186.854M info
ARTV
May 08, 2026, 4:24 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $11.07
Real-time Price: $3.82 info
Change: -$7.25 (-65%) info
Market Cap: $186.854M info
ARTV
May 08, 2026, 4:22 PM EDT
Filing Type: 424B5
Importance Score:
9
Price at Filing: $11.07
Real-time Price: $3.82 info
Change: -$7.25 (-65%) info
Market Cap: $186.854M info
ARTV
May 08, 2026, 7:08 AM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $14.65
Real-time Price: $3.82 info
Change: -$10.83 (-74%) info
Market Cap: $186.854M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets